5 assets in Undifferentiated High Grade Pleomorphic Sarcoma Of Bone

Therapeutic assets addressing Undifferentiated High Grade Pleomorphic Sarcoma Of Bone, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Undifferentiated High Grade Pleomorphic Sarcoma Of Bone	M.D. Anderson Cancer Center	P2	CCC (53)
Fludarabine Undifferentiated High Grade Pleomorphic Sarcoma Of Bone	M.D. Anderson Cancer Center	P2	CCC (53)
Ipilimumab Undifferentiated High Grade Pleomorphic Sarcoma Of Bone	M.D. Anderson Cancer Center	P2	CCC (53)
Lifileucel Undifferentiated High Grade Pleomorphic Sarcoma Of Bone	M.D. Anderson Cancer Center	P2	CCC (53)
Nivolumab Undifferentiated High Grade Pleomorphic Sarcoma Of Bone	M.D. Anderson Cancer Center	P2	CCC (53)